Azithromycin for bronchial asthma in adults: An effectiveness trial / 65

J Am Bd Fam Med 2012; 25:442-459.*** This clinical trial (called AZMATICS) found that azithromycin had significant benefits for the majority of subjects with severe, treatment resistant asthma who elected to take azithromycin.

This trial was “approved” but not funded by the National Institutes of Health (NIH), therefore it was not able to enroll the 600+ subjects originally planned, nor were tests for infection possible.

Among the stated reasons for declining to fund AZMATICS, the NIH review summary stated “it remained the opinion of the committee that current and former smokers should be excluded from the study” and “The committee felt that the need for a “real world” setting for this trial was overemphasized…”

View Article